Rosemary Gibson is an award-winning author of China Rx: Exposing the Risks of America’s Dependence on China for Medicine which reveals the dramatic shift in where medicines are made and growing concerns about their quality. It highlights the centralization of the global supply of medicines in a single country and implications in the event of a global pandemic, natural disaster, or geopolitical event.
Ms. Gibson is Senior Advisor at the Hastings Center and Perspectives Editor at JAMA Internal Medicine. She is recipient of the highest honor from the American Medical Writers Association for her outstanding contributions to the public’s interest in reporting on critical health care issues. The American Pharmacists Association Foundation recognized Rosemary with the 2019 Pinnacle Award for career achievement.
She has been quoted in the Financial Times, Bloomberg, The Hill, Bloomberg Law, Washington Times, U.S. News and World Report, Detroit News, Des Moines Register, NBC.com, Deseret News, Military Officer, among others. She has appeared on Fox News, Fox Business News, the Economic War Room, NPR Innovation Hub, the Ralph Nader Radio Hour, among other media venues. She testified before the U.S.-China Economic and Security Review Commission and is working to promote common sense solutions.
Her first book, Wall of Silence, puts a human face on the Institute of Medicine report, To Err is Human. Treatment Trap, Battle Over Health Care, and Medicare Meltdown chronicle the behind-the-scenes forces that shape health care today. Besides China Rx, her favorite topics to discuss or keynote on are healthcare, healthcare reform, Medicare, and most of all, patient safety.
Rosemary Gibson is Senior Advisor at the Hastings Center and Perspectives Editor for JAMA
At the Robert Wood Johnson Foundation, Rosemary was chief architect of its twelve-year $250
million national strategy to establish palliative care in the nation’s hospitals. Today, more than
1800 hospitals have a palliative care program, an increase from about 10 in the 1990s. Ms.
Gibson worked with Bill Moyers on the PBS documentary, “On Our Own Terms.” She is recipient
of the Lifetime Achievement Award from the American Academy of Hospice and Palliative
While at the Foundation, Ms. Gibson led national quality improvement and patient safety
initiatives working in partnership with the Institute for Healthcare Improvement. She funded the
first rapid response systems in two hundred hospitals, among other safety innovations.
Ms. Gibson served as 2019 Co-Chair of the IHI National Patient Safety Congress and will do so
again in 2020. She is on the board of the MedStar Institute for Quality and Patient Safety and
serves as faculty for a four-day summer immersion program in patient safety for medical and
nursing students and residents, the Academy of Emerging Leaders in Patient Safety: The
Telluride Experience which has graduated more than 1300 students and residents.
Ms. Gibson is a board member of the Accreditation Council for Graduate Medical Education, and
served for six years on the inaugural ACGME CLER Evaluation Committee to advance patient
safety in teaching hospitals and other clinical learning environments.
She has given grand rounds and patient safety presentations at hundreds of hospitals; keynoted
meetings of the National Quality Forum, The Joint Commission, AONE, National Council of State
Boards of Nursing, Federation of State Medical Boards, National Summit on Overuse held by The
Joint Commission and AMA, Society of Critical Care Medicine, the Joint Commission of
Pharmacy Practitioners, among others. She has been faculty for the Dartmouth Summer
Symposium on Quality Improvement and was its 2013 “wizard.” She received the Lewis
Blackman Patient Safety Award from the South Carolina Hospital Association. Ms. Gibson is the recipient of the highest honor from the American Medical Writers Association for her outstanding contributions to the public’s interest in reporting on critical health care issues.
Her first book, Wall of Silence, puts a human face on the Institute of Medicine report, To
Err is Human. Treatment Trap, Battle Over Health Care, and Medicare Meltdown chronicle the
behind-the-scenes forces that shape health care today.
Her most recent book, China Rx: Exposing the Risks of America’s Dependence on China for
Medicine, reveals the dramatic shift in where medicines are made and growing concerns about
the quality of medicines. It highlights the centralization of the global supply of medicines in a
single country that creates vulnerabilities in the event of a global pandemic, natural disaster, or
Her books have been reviewed in Publishers Weekly, Washington Post, JAMA, Health Affairs;
referenced in proceedings of the U.S. Senate; mentioned in Congressional testimony; noted in
the WSJ, Financial Times, NYT, USA Today, Consumer Reports, and Boston Globe, O Magazine,
Reader’s Digest, US News and World Report, Medscape, Modern Healthcare, AARP Magazine
and AARP Bulletin. China Rx was one of 100 books featured at the 2018 National Press Club
Ms. Gibson has appeared on Chicago Tonight, WBGH’s Greater Boston, The Doctors, Fox Nightly
News, Fox Business News, Full Measure with Sharyl Atkisson, C-Span, and hundreds of radio
programs including WGBH Innovation Hub and the Ralph Nader Radio Hour.
Ms. Gibson graduated summa cum laude from Georgetown University and has a master’s
degree from the London School of Economics.
Millions of Americans are taking prescription drugs made in China and don’t know it–and pharmaceutical companies are not eager to tell them.
Several decades ago, penicillin, vitamin C, and many other prescription and over-the-counter products were manufactured in the United States. But with the rise of globalization, antibiotics, antidepressants, birth control pills, blood pressure medicines, cancer drugs, among many others are made in China and sold in the United States.
China’s biggest impact on the US drug supply is making essential ingredients for thousands of medicines found in American homes and used in hospital intensive care units and operating rooms.
Rosemary Gibson convincingly argues that there are at least two major problems with this scenario. First, it is inherently risky for the United States to become dependent on any one country as a source for vital medicines, especially given the uncertainties of geopolitics. For example, if an altercation in the South China Sea causes military personnel to be wounded, doctors may rely upon medicines with essential ingredients made by the adversary.
Second, lapses in safety standards and quality control in Chinese manufacturing are a risk. Citing the concerns of FDA officials and insiders within the pharmaceutical industry, the authors document incidents of illness and death caused by contaminated medications that prompted reform.
This talk based on her book China Rx, examines the implications of our reliance on China on the quality and availability of vital medicines.
MORE SPEECH TOPICS COMING SOON.
“China Rx is a must-read for everyone who takes, makes, regulates, or sells a prescription drug or an over-the-counter medicine. It is a heroic and critical exploration into one of the greatest threats to both our national and health securities…. This is scarier than a Stephen King novel.”
—Michael T. Osterholm, Regents Professor, University of Minnesota, and author of Deadliest Enemy: Our War Against Killer Germs
“China Rx…reveals how the loss of the manufacturing capability and control of the supply of critical medicines, and their component ingredients, endangers the medical future of the American public while also posing a serious threat to our economy….
—Edwin Meese III, 75th United States attorney general
“Everyone who has ever taken a pill needs to read this book. The American people won’t be happy when they find out that many of the medicines they rely on are being made in China…”
—Leo W. Gerard, international president, United Steelworkers
“…China Rx is a wake-up call for the public and policy makers to bring drug manufacturing home, safeguard American jobs, and strengthen national security.”
—Scott N. Paul, president, Alliance for American Manufacturing
“China Rx is a compelling book that reveals America’s troubling dependence on China for essential medicines and the pattern in US-China trade where intellectual property and value-added production are shifted to China to the detriment of US workers, businesses, national security, and the health of our citizens.”
—Daniel Slane, commissioner, US-China Economic and Security Review Commission
“The authors tell how the institutions we trust have sold out to China and thrown American patients under the bus! …I am appalled that so many people care more about cost than the quality of our medicines. China Rx would make a great suspense thriller movie.”
—Martin VanTrieste, former senior vice president for quality, Amgen
“…Rosemary Gibson and Janardan Prasad Singh do an outstanding job of guiding the reader through the inherent risk to the United States to become dependent on any one country, such as China, as a source for vital medicines, and the risks from weak enforcement of safety standards and quality control by foreign manufacturers.”
—Major General. Larry J. Lust, US Army (ret.)
“China Rx opens our eyes to another key industry whose intellectual property and productive capacity are being transferred to China…..”
—Patrick A. Mulloy, former assistant secretary, US Department of Commerce International Trade Administration
“China Rx exposes the scary truth that a great number of prescription drugs and over-the-counter medicines in the United States have ingredients from China. There should be tougher import standards, a requirement for pharmaceutical companies to label a drug’s origins, and a reversal of US dependence on China.”
—Jim Guest, former president, Consumer Reports
“China Rx makes an overwhelming case for the pharmaceutical industry to board the reshoring train….”
—Harry C. Moser, founder and president, Reshoring Initiative